Join Growin Stock Community!

Fractyl health, inc. common stockGUTS.US Overview

US StockHealthcare
(No presentation for GUTS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GUTS AI Insights

GUTS Overall Performance

GUTS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GUTS Recent Performance

2.64%

Fractyl health, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

GUTS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GUTS Key Information

GUTS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GUTS Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Price of GUTS

GUTS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GUTS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23992.50
PB Ratio
1.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-4073233.33%
Revenue Growth (YoY)
-96.91%
Profit Growth (YoY)
-93.33%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23992.50
PB Ratio
1.86
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-4073233.33%
Revenue Growth (YoY)
-96.91%
Profit Growth (YoY)
-93.33%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%
  • When is GUTS's latest earnings report released?

    The most recent financial report for Fractyl health, inc. common stock (GUTS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GUTS's short-term business performance and financial health. For the latest updates on GUTS's earnings releases, visit this page regularly.

  • How is GUTS's revenue growth?

    In the latest financial report, Fractyl health, inc. common stock (GUTS) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does GUTS have?

    As of the end of the reporting period, Fractyl health, inc. common stock (GUTS) had total debt of 62.18M, with a debt ratio of 0.54. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GUTS have?

    At the end of the period, Fractyl health, inc. common stock (GUTS) held Total Cash and Cash Equivalents of 77.66M, accounting for 0.68 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GUTS's EPS continuing to grow?

    According to the past four quarterly reports, Fractyl health, inc. common stock (GUTS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.71. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GUTS?

    Fractyl health, inc. common stock (GUTS)'s Free Cash Flow (FCF) for the period is -22.72M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 24.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GUTS?

    The latest valuation data shows Fractyl health, inc. common stock (GUTS) has a Price-To-Earnings (PE) ratio of -1.27 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.